Profound Medical Corp. (NASDAQ:PROF) Shares Acquired by Bleichroeder LP

Bleichroeder LP grew its stake in Profound Medical Corp. (NASDAQ:PROF - Free Report) by 37.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 183,333 shares of the company's stock after buying an additional 50,000 shares during the quarter. Profound Medical accounts for about 0.3% of Bleichroeder LP's portfolio, making the stock its 29th largest holding. Bleichroeder LP owned about 0.61% of Profound Medical worth $1,377,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in shares of Profound Medical in the fourth quarter worth approximately $114,000. MTM Investment Management LLC lifted its holdings in Profound Medical by 10.4% in the 4th quarter. MTM Investment Management LLC now owns 18,575 shares of the company's stock valued at $139,000 after purchasing an additional 1,750 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Profound Medical by 201.6% during the fourth quarter. Marshall Wace LLP now owns 36,216 shares of the company's stock worth $272,000 after buying an additional 24,208 shares in the last quarter. Northwest & Ethical Investments L.P. raised its position in shares of Profound Medical by 94.9% in the fourth quarter. Northwest & Ethical Investments L.P. now owns 46,200 shares of the company's stock valued at $346,000 after buying an additional 22,500 shares during the last quarter. Finally, Truist Financial Corp purchased a new position in shares of Profound Medical in the fourth quarter worth about $376,000. 47.86% of the stock is owned by institutional investors and hedge funds.

Profound Medical Stock Down 3.0 %

Shares of Profound Medical stock traded down $0.15 during trading hours on Wednesday, reaching $4.81. 67,198 shares of the company were exchanged, compared to its average volume of 60,355. Profound Medical Corp. has a 1 year low of $3.90 and a 1 year high of $11.42. The firm has a market cap of $144.55 million, a PE ratio of -3.59 and a beta of 0.44. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.16 and a current ratio of 6.12. The stock's fifty day moving average is $5.67 and its 200 day moving average is $6.78.

Profound Medical (NASDAQ:PROF - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.11. The business had revenue of $4.18 million for the quarter, compared to analyst estimates of $5.92 million. Profound Medical had a negative net margin of 349.41% and a negative return on equity of 85.22%. As a group, equities research analysts forecast that Profound Medical Corp. will post -1.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital cut their price objective on shares of Profound Medical from $17.00 to $11.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.